Professor Jérôme Frenette is a researcher with a background in physical therapy and post-graduate training in muscle physiology and immunology at the University of California in Los-Angeles. He is a full-time researcher at the Centre de recherche du CHU de Québec-Laval University, and full professor in the department of rehabilitation at Laval University’s School of Medicine. He has been the principal investigator on several CIHR and NSERC grants. Many of his publications, and one CIHR grant were recognized and rewarded as being among the best in the field of muscle physiology. He started his career as a researcher by investigating the roles played by blood cells and mechanical loading in models of tendon injury and muscle atrophy/regrowth. In 2005, he expanded his research program to include the Buruli Ulcer, which is caused by mycobacterium ulcerans, a neglected disease of wet tropical zones, that is closely related to tuberculosis and leprosy. His research group was the first to show that mycobacterium ulcerans and its toxin, mycolactone, extend well beyond the skin, and severely affect underlying skeletal muscles. Today, the focus of his research program is to understand the link between osteoporosis and muscle atrophy/disease through one common pathway i.e. the RANK/RANKL/OPG pathway. In collaboration with Duchenne muscular dystrophy foundations in Canada, the United States and Australia, as well as sustainable financial support from public and private sources, his team is developing new drugs that would potentially alleviate, in tandem, osteoporosis and muscle degeneration in Duchenne muscular dystrophy patients or other forms of bone and muscle diseases.
2705, boulevard Laurier
P-09800
Québec, Québec
Canada G1V 4G2
- Argaw, AntenehEmployeeCHUL+1 418-525-4444, extension 48840Anteneh.Argaw@crchudequebec.ulaval.ca
2705, boulevard Laurier
P-09800
Québec, Québec
Canada G1V 4G2 - Bouredji, ZinebEmployeeCHUL+1 418-525-4444, extension 47954zineb.bouredji.1@ulaval.cazineb.bouredji@crchudequebec.ulaval.ca
2705, boul. Laurier
P-09800
Québec, Québec
Canada G1V 4G2 - Facchin, AnthonyDoctoral studentCHUL+1 418-525-4444, extension 47954anthony.facchin.1@crchudequebec.ulaval.caanthony.facchin.1@ulaval.ca
2705, boulevard Laurier
P-09800
Québec, QC
Canada G1V 4G2
No benefit of vitamin D supplementation on muscle function and health-related quality of life in primary cardiovascular prevention patients with statin-associated muscle symptoms: A randomized controlled trial
Journal ArticleJ Clin Lipidol, 18 (2), 2024.
Lack of association between four biomarkers and persistent post-concussion symptoms after a mild traumatic brain injury
Journal ArticleJ Clin Neurosci, 118 , 2023.
Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy
Journal ArticleCalcif Tissue Int, 113 (4), 2023.
Impact of statin withdrawal on perceived and objective muscle function
Journal ArticlePLoS One, 18 (6), 2023.
RANKL Inhibition Reduces Cardiac Hypertrophy in mdx Mice and Possibly in Children with Duchenne Muscular Dystrophy
Journal ArticleCells, 12 (11), 2023.
The Association Between Self-Reported Cigarette Smoking and Spinal Pain is Not Explained by Serum Cotinine Levels
Journal ArticleAnn Epidemiol, 67 , 2022.
The Roles of RANK/RANKL/OPG in Cardiac, Skeletal, and Smooth Muscles in Health and Disease
Journal ArticleFront Cell Dev Biol, 10 , 2022.
Post-Concussion Symptoms Rule: Derivation and Validation of a Clinical Decision Rule for Early Prediction of Persistent Symptoms after a Mild Traumatic Brain Injury
Journal ArticleJ Neurotrauma, 39 (19-20), 2022.
The inflammatory response, a mixed blessing for muscle homeostasis and plasticity
Journal ArticleFront Physiol, 13 , 2022.
S100B protein level for the detection of clinically significant intracranial haemorrhage in patients with mild traumatic brain injury: a subanalysis of a prospective cohort study
Journal ArticleEmerg Med J, 38 (4), 2021.
Active projects
- Decipher the physiological functions of osteoprotegerin in skeletal and cardiac muscles, from 2023-04-01 to 2028-03-31
- Multifunctional properties of osteoprotegerin in muscular dystrophy and muscle repair, from 2020-04-01 to 2025-03-31
Recently finished projects
- Development of a glycobiology therapy to mitigate the progression of Duchenne muscular dystrophy, from 2021-07-01 to 2023-02-28
- Development of a monosaccharide therapy using N-acetylglucosamine to mitigate Duchenne muscular dystrophy, from 2021-05-31 to 2024-05-30
- Investigation of the role of galectin-3 and its ligands in skeletal muscle strength, regeneration, and pathology, from 2018-10-01 to 2023-03-31